Toward an Optimized Therapy for Tuberculosis? Drugs in Clinical Trials and in Preclinical Development

Clinics in Chest Medicine

Volumn 30, Issue 4, 2009, Pages 755-768

  Ma, Zhenkun ^a   Lienhardt, Christian ^b  

^a GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Chemotherapy; Drug combination; Drug persistence; Drug resistance; MDR TB; Novel mechanism of action; Tuberculosis; XDR TB

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHAMBUTOL PLUS ISONIAZID; ETHIONAMIDE; ETHYLENEDIAMINE; GATIFLOXACIN; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; NITROIMIDAZOLE DERIVATIVE; OFLOXACIN; OXAZOLIDINONE DERIVATIVE; PROTEINASE INHIBITOR; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAMYCIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STREPTOMYCIN; TERIZIDONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG PENETRATION; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANIMALS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 71849104520     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2009.08.011     Document Type: Review

References (75)

1. World Health Organization. Global tuberculosis control-epidemiology, strategy, financing (2009), World Health Organization, Geneva WHO/HTM/TB/2009.411
2. Jones D., Metzger H.J., Schatz A., et al. Control of gram-negative bacteria in experimental animals by streptomycin. Science 100 2588 (1944) 103-105
3. Fox W. Whither short-course chemotherapy?. Br J Dis Chest 75 (1981) 331-357
4. Fox W., Ellard G.A., and Mitchison D.A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986. Int J Tuberc Lung Dis 3 10 (1999) S231-S279
5. World Health Organization. Treatment of tuberculosis: guidelines for national programmes (2003), World Health Organization, Geneva WHO/CDS/TB/2003.313
6. Jindani A., Nunn A.J., and Enarson D.A. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 364 (2004) 1244-1251
7. Mitchison D.A. Basic mechanisms of chemotherapy. Chest 76 (1979) 771-781
8. Mitchison D.A. Treatment of tuberculosis. The Mitchell lecture 1979. J R Coll Physicians Lond 14 (1980) 91-95 and 98-99
9. McCune Jr. R.M., and Tompsett R. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med 104 (1956) 737-762
10. International Union Against Tuberculosis and Lung Disease. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization. Tuber Lung Dis 75 3 (1994) 180-181
11. Quality assurance of fixed-dose combinations of anti-tuberculosis medications. Proceedings of an IUATLD/WHO workshop, 29th IUATLD World Conference. Int J Tuberc Lung Dis 3 11 (1999) S281-S388
12. Mukherjee J.S., Rich M.L., Socci A.R., et al. Programmes and principles in treatment of multidrug resistant tuberculosis. Lancet 363 9407 (2004) 474-481
13. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis (2006), World Health Organization, Geneva WHO/HTM/TB/2006.361
14. Nathanson E., Gupta R., Huamani P., et al. Adverse events in the treatment of multidrug-resistant tuberculosis: Results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 8 (2004) 1382-1384
15. Cobelens F.G., Heldal E., Kimerling M.E., et al. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med 5 7 (2008) e150
16. Espinal M., and Farmer P. The Cambridge declaration: towards clinical trials for drug-resistant tuberculosis. Int J Tuberc Lung Dis 13 (2009) 1-2
17. Lawn S.D., Badri M., and Wood R. Risk factors for tuberculosis among HIV-infected patients receiving antiretroviral treatment. Am J Respir Crit Care Med 172 10 (2005) 1348
18. Niemi M., Backman J.T., Fromm M.F., et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharm 42 (2003) 819-850
19. Lawn S.D., Gail-Bekker L., and Miller R. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 5 (2005) 361-373
20. Jereb J., Etkind S.C., Joglar O.T., et al. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 7 Suppl 3 (2003) S384-S390
21. IUAT. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 60 (1982) 555-564
22. Comstock G.W., Baum C., and Snider Jr. D.E. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies. Am Rev Respir Dis 119 (1979) 827-830
23. Smieja M.J., Marchetti C.A., Cook D.J., et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 1 (1999) CD001363
24. British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Joint Tuberculosis Committee of the British Thoracic Society. Thorax 55 (2000) 887-901
25. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161 (2000) S221-S247
26. Spyridis N.P., Spyridis P.G., Gelesme A., et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 45 6 (2007) 715-722
27. Corbett E.L., Watt C.J., Walker N., et al. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch Intern Med 163 (2003) 1009-1021
28. Woldehanna S., and Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 3 (2006) CD000171
29. Gray D.M., Zar H., and Cotton M. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. Cochrane Database Syst Rev 1 (2009) CD006418
30. Stop T.B. Partnership working group on new drugs. Working group TB drug R&D portfolio. Web publication. Available at: http://www.stoptb.org/wg/new_drugs/projects.asp.
31. Hu Y., Coates A.R., and Mitchison D.A. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrobial Agents Chemother 47 (2003) 653-657
32. Paramasivan C.N., Sulochana S., Kubendiran G., et al. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrobial Agents Chemother 49 (2005) 627-631
33. Rodriguez J.C., Ruiz M., Climent A., et al. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 17 (2001) 229-231
34. Sulochana S., Rahman F., and Paramasivan C.N. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J Chemother 17 (2005) 169-173
35. Alvirez-Freites E.J., Carter J.L., and Cynamon M.H. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrobial Agents Chemother 46 (2002) 1022-1025
36. Cynamon M.H., and Sklaney M. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrobial Agents Chemother 47 (2003) 2442-2444
37. Johnson J.L., Hadad D.J., Boom W.H., et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 10 6 (2006) 605-612
38. Rustomjee R., Lienhardt C., Kanyok T., et al. A Phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 12 2 (2008) 128-138
39. Miyazaki E., Miyazaki M., Chen J.M., et al. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrobial Agents Chemother 43 (1999) 85-89
40. Nuermberger E.L., Yoshimatsu T., Tyagi S., et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169 (2004) 421-426
41. Gosling R.D., Uiso L.O., Sam N.E., et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 168 (2003) 1342-1345
42. Pletz M.W.R., De Roux A., Roth A., et al. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrobial Agents Chemother 48 3 (2004) 780-782
43. Burman W.J., Goldberg S., Johnson J.L., et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174 (2006) 331-338
44. Conde M.B., Efron A., Loredo C., et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled Phase II trial. Lancet 373 (2009) 1183-1189
45. Ginsberg A.M., and Spigelman M. Challenges in tuberculosis drug research and development. Nat Med 13 3 (2007) 290-294
46. Ma Z., Ginsberg A.M., and Spigelman M. In: Taylor J.B., and Triggle D. (Eds). Comprehensive medicinal chemistry II. Antibacterial: anti-mycobial agents vol 7 (2007), Elsevier, Oxford 699-730
47. Maddix D.S., Tallian K.B., and Mead P.S. Rifabutin: a review with emphasis on its role in the prevention of disseminated Mycobacterium avium complex infection. Ann Pharmacother 28 11 (1994) 1250-1254
48. Davies G., Cerri S., and Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 4 (2007) CD005159
49. Munsiff S.S., Kambili C., and Ahuja S.D. Rifapentine for the treatment of pulmonary tuberculosis. Clin Infect Dis 43 11 (2006) 1468-1475
50. Temple M.E., and Nahata M.C. Rifapentine: its role in the treatment of tuberculosis. Ann Pharmacother 33 11 (1999) 1203-1210
51. The Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 360 9332 (2002) 528-534
52. Rosenthal I.M., Williams K., Tyagi S., et al. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med 178 9 (2008) 989-993
53. Rosenthal I.M., Zhang M., Williams K.N., et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4 12 (2007) e344
54. Andries K., Verhasselt P., Guillemont J., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307 (2005) 223-227
55. Lounis N., Veziris N., Chauffour A., et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrobial Agents Chemother 50 (2006) 3543-3547
56. Lenaerts A.J., Hoff D., Aly S., et al. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by R207910. Antimicrobial Agents Chemother 51 9 (2007) 3338-3345
57. Veziris N., Ibrahim M., Lounis N., et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med 179 1 (2009) 75-79
58. Rustomjee R., Diacon A.H., Allen J., et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC-207 in treatment of pulmonary tuberculosis. Antimicrobial Agents Chemother 52 8 (2008) 2831-2835
59. Diacon A.H., Pym A., Grobusch M., et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360 (2009) 2397-2405
60. Singh R., Manjunatha U., Boshoff H.I., et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322 5906 (2008) 1392-1395
61. Stover C.K., Warrener P., VanDevanter D.R., et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405 6789 (2000) 962-966
62. Matsumoto M., Hashizume H., Tomishige T., et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3 11 (2006) e466
63. Tyagi S., Nuermberger E., Yoshimatsu T., et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrobial Agents Chemother 49 6 (2005) 2289-2293
64. Ginsberg AM, Diacon A. Update on PA-824. Symposium 12: Recent Advances in TB Drug Development, 39th Union World Conference on Lung Health 2008; Paris.
65. Protopopova M., Hanrahan C., Nikonenko B., et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. Antimicrobial Agents Chemother 56 (2005) 968-974
66. Jia L., Noker P.E., Coward L., et al. Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol 147 5 (2006) 476-485
67. Nikonenko B.V., Protopopova M., Samala R., et al. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrobial Agents Chemother 51 4 (2007) 1563-1565
68. Diekema D.J., and Jones R.N. Oxazolidinone antibiotics. Lancet 358 9297 (2001) 1975-1982
69. Sood R., Bhadauriya T., Rao M., et al. Antimycobacterial activities of oxazolidinones: a review. Infect Disord Drug Targets 6 4 (2006) 343-354
70. Dietze R., Hadad D.J., McGee B., et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 178 11 (2008) 1180-1185
71. Ntziora F., and Falagas M.E. Linezolid for the treatment of patients with mycobacterial infections: a systematic review. Int J Tuberc Lung Dis 11 6 (2007) 606-611
72. Cynamon M.H., Klemens S.P., Sharpe C.A., et al. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrobial Agents Chemother 43 5 (1999) 1189-1191
73. Williams 2008. Williams K.N., Stover C.K., Zhu T., et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrobial Agents Chemother 53 4 (2009) 1314-1319
74. Brown D., and Super-Furga G. Rediscovering the sweet spot in drug discovery. Drug Discov Today 8 (2003) 1067-1077
75. Schluger N., Karunakara U., Lienhardt C., et al. Building clinical trials capacity for tuberculosis drugs in high-burden countries. PLoS Med 4 11 (2007) e302